Search research articles
Contact Us
Filters
Showing results (51-60 of 95) with videos related to
Page
of 10
Sort By:
Journal of Neurology
|
May 3, 2002
T cell vaccination in multiple sclerosis: results of a preliminary study
Jingwu Z Zhang, Victor M Rivera, Maria V Tejada-Simon, et al.
Acta Neurologica Belgica
|
May 15, 2013
Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosis
Miguel A Macías-Islas, Isaac F Soria-Cedillo, Merced Velazquez-Quintana, et al.
Cancer Chemotherapy and Pharmacology
|
March 8, 2013
Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models
Joseph M Gozgit, Rachel M Squillace, Matthew J Wongchenko, et al.
Cancer Chemotherapy and Pharmacology
|
November 1, 2011
Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial
David A Reardon, Patrick Y Wen, W K Alfred Yung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 3, 2008
A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies
David A Rizzieri, Eric Feldman, John F Dipersio, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 20, 2011
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
Ryohei Katayama, Tahsin M Khan, Cyril Benes, et al.
Molecular Cancer Therapeutics
|
January 13, 2012
Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models
Joseph M Gozgit, Matthew J Wong, Lauren Moran, et al.
Molecular Cancer Therapeutics
|
April 13, 2011
Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens
Victor M Rivera, Rachel M Squillace, David Miller, et al.
Chemical Biology & Drug Design
|
December 2, 2010
Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance
Tianjun Zhou, Lois Commodore, Wei-Sheng Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 26, 2018
Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias
Michael W Schmitt, Justin R Pritchard, Scott M Leighow, et al.
Page
of 10
Search research articles
Search
Showing results (51-60 of 95) with videos related to
Sort By:
Page
of 10
Journal of Neurology
|
May 3, 2002
T cell vaccination in multiple sclerosis: results of a preliminary study
Jingwu Z Zhang, Victor M Rivera, Maria V Tejada-Simon, et al.
Acta Neurologica Belgica
|
May 15, 2013
Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosis
Miguel A Macías-Islas, Isaac F Soria-Cedillo, Merced Velazquez-Quintana, et al.
Cancer Chemotherapy and Pharmacology
|
March 8, 2013
Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models
Joseph M Gozgit, Rachel M Squillace, Matthew J Wongchenko, et al.
Cancer Chemotherapy and Pharmacology
|
November 1, 2011
Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial
David A Reardon, Patrick Y Wen, W K Alfred Yung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 3, 2008
A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies
David A Rizzieri, Eric Feldman, John F Dipersio, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 20, 2011
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
Ryohei Katayama, Tahsin M Khan, Cyril Benes, et al.
Molecular Cancer Therapeutics
|
January 13, 2012
Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models
Joseph M Gozgit, Matthew J Wong, Lauren Moran, et al.
Molecular Cancer Therapeutics
|
April 13, 2011
Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens
Victor M Rivera, Rachel M Squillace, David Miller, et al.
Chemical Biology & Drug Design
|
December 2, 2010
Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance
Tianjun Zhou, Lois Commodore, Wei-Sheng Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 26, 2018
Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias
Michael W Schmitt, Justin R Pritchard, Scott M Leighow, et al.
Page
of 10